Evidence map›Paper›PMID 38079088›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Comparing the survival rates of patients with stage IIIC endometrial cancer undergoing sandwich therapy to those undergoing sequential chemotherapy and radiotherapy: a meta-analysis.

Meng-Meng Zhang, Yu-Kun Chen, Li Shi, Jing Ma, Jing-De Jia, Xi-Wa Zhao

Abstract readMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Meng-Meng Zhang *Department of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China.
Yu-Kun Chen *Department of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China.
Li ShiDepartment of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China.
Jing MaDepartment of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China.
Jing-De JiaDepartment of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China.
Xi-Wa ZhaoDepartment of Obstetrics and Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Jiankanglu 12, Shijiazhuang, 050011, China. zhaoxiwa@hebmu.edu.cn.ORCID http://orcid.org/0009-0007-2329-2842
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of additional treatment after surgery for stage IIIC endometrial cancer (EC) according to the Federation of Gynecology and Obstetrics (FIGO) is still a topic of discussion. This meta-analysis examined the effects of sandwich treatment and sequential treatment on the survival of individuals diagnosed with stage IIIC EC.

methodsWe examined the literature from various databases regarding the overall survival (OS) and adverse effects of the two additional therapies following surgery in individuals diagnosed with stage IIIC EC. Revman 5.4.1 was utilized to combine hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI) for OS and toxicities.

resultsThe findings comprised of five retrospective investigations involving a combined total of 800 individuals. The patients who underwent sandwich treatment did not demonstrate a notable improvement in survival rates over a period of 3 years. Upon eliminating the impact of extensive samples, it was discovered that sandwich therapy exhibited a superior 5-year overall survival compared to patients receiving sequential therapy. The effectiveness of sandwich therapy was superior to sequential therapy in terms of a 3-year OS for non-endometrioid histology, although the outcome did not reach statistical significance. The toxicities of both treatments were similar.

conclusionsIn terms of long-term survival, sandwich therapy was found to be more advantageous than sequential therapy for patients with stage IIIC EC, with no significant disparity observed in the 3-year OS and toxicities between the two treatments. Sandwich therapy exhibited a tendency towards improved effectiveness in patients with histology other than endometrioid.

Indexed as

Endometrial NeoplasmsNeoplasm StagingCombined Modality TherapyFemaleHumansRetrospective StudiesSurvival RateOverall survivalSandwich therapySequential therapyStage IIIC endometrial cancerToxicity

Identifiers

PMID38079088
OpenAlexW4389553457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.